In the article, “The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori”,[1] which appears in Volume 99, Issue 38 of Medicine, the conflict of interest statement, “The study was funded by Ilyang, which manufactures Ilaprazole”, was left out and has since been added to the article.
Footnotes
How to cite this article: Lee SW, Moon SJ, Kim SH. The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori. Medicine. 2021;100:3(e24431).
Reference
- [1].Lee SW, Moon SJ, Kim SH. The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori. Medicine. 2020. 99:e22137. [DOI] [PMC free article] [PubMed] [Google Scholar]